Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Stevanato Group (NYSE: STVN) has announced a non-exclusive agreement with DWK Life Sciences to distribute its EZ-fill® Ready-to-Use (RTU) solutions. This collaboration aims to enhance the distribution of EZ-fill® products, which include vials and cartridges specifically designed for pharmaceutical use. The EZ-fill® technology has been widely adopted, with over 250 installations in the last 12 years, ensuring quality improvements and reduced costs. The partnership is expected to leverage DWK’s extensive laboratory network to expand Stevanato's market reach.
Stevanato Group S.p.A (NYSE: STVN) will release its third-quarter 2022 financial results on November 8, 2022, at 6:30 a.m. (ET). The company will host a conference call and webcast to discuss these results at 8:30 a.m. (ET) on the same day, which will include a slide presentation available on its Investor Relations webpage.
Participants can pre-register for immediate access, while those unable to do so may dial in directly. The archived webcast will be accessible for three months post-event.
Bexson Biomedical and Stevanato Group have been jointly awarded the PDA's 2022 Drug Delivery Innovation Partnership Award for their collaboration on the On Body Delivery System (OBDS). This recognition highlights their innovative work in optimizing drug delivery solutions for non-opioid pain management, particularly with Bexson's SEVALENT™ formulation technology. The award was presented at the PDA conference in Palm Springs, CA on October 18, 2022. Bexson’s lead therapy, BB106, targets a $36 billion market.
Stevanato Group (NYSE: STVN) announced its participation in the Bank of America Global Healthcare Conference on September 15, 2022, at 9:05 a.m. BST in London. The event highlights the company's role as a leading provider of drug containment and delivery solutions. Interested investors can access a webcast via the company's website under the 'News & Events' section. Founded in 1949, Stevanato Group provides integrated solutions for the pharmaceutical and life sciences industries, focusing on innovation and engineering excellence.
Stevanato Group (NYSE: STVN) and Gerresheimer AG have announced their collaboration to develop a new Ready-To-Use (RTU) vial solution based on Stevanato's EZ-fill® technology. This initiative aims to enhance quality, efficiency, and reduce the total cost of ownership for pharmaceutical companies. The partnership addresses the rising demand for RTU vials, with a focus on standardizing fill-finish operations. The new solution will significantly lower particle load, bolstering overall quality. The platform will be showcased at the CPhI Worldwide in Frankfurt in November 2022.
Stevanato Group (NYSE: STVN) reported a strong second quarter of 2022, achieving a 15% revenue growth to €234.2 million. The company raised its full-year guidance, projecting revenue between €955 million and €965 million. Adjusted diluted EPS was €0.12, with a 31.8% gross profit margin. The backlog rose 37% to approximately €1.01 billion, driven by increased demand in Biopharmaceutical and Diagnostic Solutions. Despite lower COVID-19-related revenue, the Core business showed robust demand.
Stevanato Group (NYSE: STVN) will release its second quarter 2022 financial results on August 4, 2022, at 6:30 a.m. EST. A conference call and webcast will follow at 8:30 a.m. EST to discuss the results, accompanied by a slide presentation available on their Investor Relations webpage. Interested participants can pre-register for immediate access. The company provides drug containment, delivery, and diagnostic solutions for the pharmaceutical and biotechnology sectors, emphasizing its engineering and innovation capabilities.
Summary not available.
Stevanato Group S.p.A. (NYSE: STVN) announced that all resolutions proposed at its Annual General Meeting (AGM) on June 1, 2022 were approved. This includes the approval of annual financial statements for the year ending December 31, 2021 and the distribution of dividends of EUR 0.051 per share, with a record date of June 14, 2022 and a payment date of July 13, 2022. Shareholders also granted new authorization for share buybacks and amendments to the articles of association.
Stevanato Group (NYSE: STVN) announced its participation in two upcoming investor conferences. On June 7, 2022, they will present at the 42nd Annual William Blair Growth Stock Conference in Chicago at 2:40 PM CST. The following day, on June 9, 2022, they will be at the Jefferies Healthcare Conference in New York City at 1:00 PM EST. Live audio webcasts will be available on their website, with replays accessible for 90 days.